1. Purpose
This document outlines the guideline details for management of pre-existing diabetes mellitus (DM) in pregnancy at the Women’s.

2. Definitions
Not applicable

3. Responsibilities
Staff providing the care for the management of pre-existing diabetes mellitus in pregnancy should follow this guideline.

4. Guideline

4.1 Pre-pregnancy counselling

Specific diabetes related measures
- The clear benefits of optimal metabolic control in reducing the risk of congenital malformations
- The clear benefits of optimal metabolic control in reducing the risk of an unhealthy baby
- An outline of routine management expectations during pregnancy including glycaemic targets; pregnancy should be delayed until HbA1c <7.0%
- Advice about contraception until conception is desired

General pre-pregnancy diabetes related measures
- Folate supplements 2.5mg/day
- Not smoking
- Reduced alcohol intake
- Review all medications (including complementary) for safety in pregnancy
- Check rubella and varicella immune status
- Pap smear if not performed within last 2 years
- FBE, blood group and antibodies
- TFT, Thyroid antibodies, Coeliac disease screen for Type 1

Specific
- When conception is anticipated more direct action is required

Medications
- Metformin can be continued with women with type 2 DM or PCOS. All other oral hypoglycaemic agents are contraindicated during pregnancy. Women with pre-existing diabetes treated with oral agents should ideally be commenced on insulin prior to conception if diabetes control is unsatisfactory.
- In special circumstances, oral agents may be of more benefit than no therapy at all.
- Antihypertensive therapy should be optimized for pregnancy. Drugs contraindicated in pregnancy should be changed prior to conception. These include; ACE inhibitors and A2 receptor blockers
- Lipid lowering therapy must be ceased
Education

- Formal review by a diabetes education and a dietician, with the goal of ensuring adequate self-management skills including sick day care. Hypoglycaemia management must be reviewed, including glucagon use by the partner. Suggestion for dealing with morning sickness could be discussed.

Complications review

- Nephropathy - a timed urine sample and serum creatinine to quantify the microalbumin excretion rate and creatinine clearance
- Retinopathy - refer to ophthalmologist, optometrist or for fundal photos if not performed in the last 12 months. Retinopathy requiring treatment should be dealt with prior to pregnancy.
- Consider the possibility of macrovascular disease and formally investigate if indicated.

Miscellaneous

- Thyroid and renal (electrolytes, urea, creatinine and uric acid) function should be measured
- Screen for coeliac disease if not previously done (total IgA, anti-gliadin and anti-transglutaminase antibodies)
- Establish a plan for very early review when pregnancy is confirmed

Contraindications to pregnancy

- The medical role is to advise women of the risks they run in undergoing a pregnancy. The decision is the woman's (couple's).
- Poor glycaemic control Hb1c > 7.0% until corrected.
- Active proliferative retinopathy until treated.
- Severe nephropathy creatinine >/= 0.25mmol/L
- Macrovascular disease

4.2 First Visit in Pregnancy

General pregnancy measures

- Perform routine antenatal screening tests, including MSU for microscopy and culture
- Provide advice about treatment of nausea and vomiting in pregnancy
- Perform Pap smear if not done in last 2 years

Diabetes related measures

- Repeat steps for pre-pregnancy counselling
- Glycaemic control
  - All patients should perform home glucose monitoring at least 4 times each day before breakfast, and 2 hours after each meal
  - The targets ≤5.0 mol/L fasting and ≤ 6.7 mmol/L after meals
  - Insulin therapy will usually be basal-bolus with at least 1 dose of medium/long-acting insulin each day and short/rapid-acting insulin before each main meal or insulin pump
  - Patients should be advised to undertake 30 minutes of exercise (e.g. brisk walking) at least 4 times per week unless medically contraindicated
  - The dietician should review all patients
  - Hb1c should be measured at the first visit and repeated monthly. The target level is <6.0%.
Screening for fetal anomalies/ aneuploidy
Mid trimester maternal serum screening is not reliable in pre-gestational diabetes. These patients should be offered combined first trimester screening of aneuploidy with HCG and PAPP-A measures at 10 weeks and an ultrasound examination for dating, nuchal translucency, gross morphology and plurality at 12 weeks.

4.3 Subsequent Visits in Pregnancy

Frequency of visits
Three weekly until 28 weeks, then 2 weekly until 34 weeks, then weekly until delivery. Patients should be seen at each visit by the obstetrician and diabetes physician.

- Patients should see the ophthalmologist each trimester

Fetal surveillance

- Ultrasound examination for morphology at 19-20 weeks
- Ultrasound examination for growth at 28-30 weeks and 34-36 weeks. More frequent ultrasound examination, including umbilical artery blood flow measurement, may be indicated with the following complicating factors:
  - Microvascular (e.g. nephrology or proliferative retinopathy) or macrovascular disease
  - Hypertension pre-existing or pregnancy-induced
  - Fetal macrosomia
  - Intrauterine growth restriction
  - Poor glycaemic control
  - Smokers

Cardiotocography should be performed weekly from 36 weeks gestation. Earlier and more intensive (more frequent CTG, Doppler flow studies, biophysical profiles) fetal monitoring may be indicated in the presence of the above complications.

4.4 Subsequent Visits in Pregnancy

Timing

- Patients with optimal glyaemic control and no complicating factors (see above) should be delivered at 38-40 weeks, with the method depending on obstetric factors. If an elective caesarean section is to be performed, it should be at 38-39 weeks.
- Patients with one of the complicating factors mentioned above should be delivered at 38-39 weeks, or earlier if indicated. Elective caesarean section should be performed at 38 weeks.
- If delivery before 36 weeks is indicated, Betamethasone to promote fetal lung maturity should be administered if possible. This will usually require admission for sliding scale insulin.

Method

- If the estimated fetal weight at the time of delivery is < 4,000 g, vaginal delivery is usually appropriate unless there are other obstetric indications for caesarean section
- If the estimated fetal weight at the time of delivery is > 4,250 g, elective caesarean section should be strongly considered because of the risk of shoulder dystocia
- If the estimated fetal weight at the time of delivery is 4,000 – 4,250 g, the decision about the route of delivery should be discussed with the patient taking into account the risks for the particular patient.
- Management of Hypoglycaemia (Clinical algorithm)

5. Evaluation, monitoring and reporting of compliance to this guideline

To be developed.
6. References
Not applicable.

7. Legislation related to this guideline
Not applicable.

8. Appendices
Not applicable.

PGP Disclaimer Statement
The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated.

In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.